Cargando…
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial
IMPORTANCE: Preclinical data suggest that poly(ADP-ribose) polymerase (PARP) inhibitors have synergistic activity when combined with immune checkpoint inhibitors (ICIs); however, it is unknown which tumor types or molecular subtypes may benefit from this combination. OBJECTIVE: To investigate respon...
Autores principales: | Yap, Timothy A., Bardia, Aditya, Dvorkin, Michael, Galsky, Matthew D., Beck, J. Thaddeus, Wise, David R., Karyakin, Oleg, Rubovszky, Gábor, Kislov, Nikolay, Rohrberg, Kristoffer, Joy, Anil Abraham, Telli, Melinda L., Schram, Alison M., Conte, Umberto, Chappey, Colombe, Stewart, Ross, Stypinski, Daria, Michelon, Elisabete, Cesari, Rossano, Konstantinopoulos, Panagiotis A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673022/ https://www.ncbi.nlm.nih.gov/pubmed/36394849 http://dx.doi.org/10.1001/jamaoncol.2022.5228 |
Ejemplares similares
-
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial
por: Schram, Alison M., et al.
Publicado: (2022) -
Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial
por: Rodon Ahnert, J., et al.
Publicado: (2023) -
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2022) -
Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study
por: Hawkes, Eliza A., et al.
Publicado: (2021) -
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial
por: Larkin, James, et al.
Publicado: (2022)